Company intelligence / Profile preview

HK inno.N Corporation

Ownership: Private
Employees: ~1695
Development stage: Commercial

Overview

HK inno.N has successfully developed and commercialized K-CAB (tegoprazan), a novel potassium-competitive acid blocker (P-CAB) for GERD. It has become the #1 A2B product in the Korean market since its launch in 2019 and is expected to achieve $100M in sales in the Korean domestic market. The company has licensed the drug to partners in China and is conducting Phase 3 trials in the US and Canada through a partnership with Sebela Pharmaceuticals.

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: Small moleculesBiopharmaceuticals
Industry: Biotech

Drug pipeline

37 assets

Closone

36 more assets in the full pipeline.

Request access →

Partnerships

Sebela Pharmaceuticals (US and Canada licensing for tegoprazan)Shandong Luoxin Pharmaceutical Group (China licensing)

Beyond the preview

Go deeper on HK inno.N Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HK inno.N Corporation.

Explore the full profile